Apr 29 |
Oculis Publishes Invitation to the Annual General Meeting
|
Apr 22 |
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
|
Apr 11 |
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
|
Apr 10 |
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
|
Apr 8 |
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
|
Apr 4 |
Oculis to Participate at Upcoming April Investor Conferences
|
Apr 1 |
Oculis files $300M mixed securities shelf
|
Mar 18 |
Oculis Holding reports Q4 results
|
Mar 18 |
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
|
Feb 28 |
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
|